Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Dec 02, 2023 8:06pm

150 Views

Post# 35765528

RE:RE:RE:RE:RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

Optimizing_the_Use_of_Accelerated_Approval-2020_0.pdf

Ongoing | Cancer Accelerated Approvals | FDA

This is what I could find so far in regards to AA for various cancer indications and it would appear onc's panc could qualify and the only limitation would be that our trial size only had if I remember N=13

<< Previous

Bullboard Posts

Next >>

One of the best Venture pharma stocks has grown even stronger